Conantokin-G vs Didemnin B
Head-to-head comparison of Conantokin-G (Conantokin-G from Conus geographus venom) and Didemnin B (Didemnin B) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Conantokin-G | Didemnin B |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Conantokin-G from Conus geographus venom | Didemnin B |
| Molecular Weight | 2,150 Da | 1112.4 Da |
| Half-Life | Minutes to hours | N/A |
| Amino Acids | 17 | N/A |
| Typical Dose | 0.1-10 nmol intrathecal|10-1000 nM in vitro|single-dose rodent studies | 0.05-2 mg/m2 IV in early trials |
| Route | Intrathecal | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 95 | 120 |
| Research Status | Pre-clinical | Clinical |
Conantokin-G Benefits
- ✓NMDA receptor antagonism
- ✓seizure-model research
- ✓excitatory neurotransmission mapping
- ✓pain-mechanism studies
Didemnin B Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓immunomodulatory
Conantokin-G Dosing
Intrathecal administration in seizure/pain models|NMDA receptor assays|In vitro excitation studies
Didemnin B Dosing
historic IV phase I/II oncology regimens|dose escalation in early trials|no approved dosing regimen
Conantokin-G Side Effects
- ⚠Sedation or dizziness in animals
- ⚠motor effects at high exposure
- ⚠off-target NMDA modulation
Didemnin B Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠myelosuppression
Research Overview
Conantokin-G
Research has shown conantokin-G can suppress NMDA-mediated responses in a sequence- and modification-dependent manner. It remains a classic marine peptide tool for probing glutamatergic signaling and analgesia-related pathways.
Didemnin B
Didemnin B showed strong cytotoxic and antiviral activity in early literature and became an important scaffold for later marine drug development. Its clinical progress was limited by toxicity, but it remains highly cited as a foundational marine depsipeptide.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.